Browse by category

Outcomes from Viking Therapeutics’ Phase 2 VENTURE clinical trial of VK2735 - a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors – reveal that after 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. The outcomes highlights the previously reported positive results from th

Both the new weight loss drugs and bariatric surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a substantial reduction in fat, researchers at Vanderbilt Health have found. Weight loss study team: From left, Danxia Yu, PhD, Zicheng Wang, MS, Lei Wang, PhD, and Jason Samuels, MD, are co-authors of a paper evaluating body composition changes after bariatric surgery or treatment with the new w

A study led by Assistant Professor Anne Loft, Associate Professor Jesper Grud Skat Madsen and Professor Susanne Mandrup from University of Southern Denmark sheds light on what happens in the fat tissue during weight loss. All three are leading researchers at the Center of Excellence ATLAS, which investigates the molecular mechanisms driving changes in liver and fat tissues in response to obesity and weight loss. This knowledge is important because obesity-induced dysfunction

Rani Therapeutics has initiated a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist, PG-102, for the treatment of obesity. RaniPill PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen, which recently announced preclinical and clinical data, at the 2025 E

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, according to a study by University of Oxford researchers. The study shows that the average rate of weight regain is 0.4kg/month after stopping treatment, with weight and risk markers for diabetes and heart disease predicted to return to pre-treatment levels in less than two years. It also finds that

Researchers at Leipzig University and the University of Gothenburg have developed a novel approach to assessing an individual's risk of metabolic diseases such as diabetes or fatty liver disease more precisely. Instead of relying solely on the widely used body mass index (BMI), the team developed an AI-based computational model using metabolic measurements. Systems view of metabolic obesity: integrating multi-organ and multi-omics signatures. Credit: Nature Medicine (2026). D